USE OF DOUBLE FIXED-DOSE COMBINATION OF OLMESARTAN AND AMLODOPINE VERSUS FIXED-DOSE COMBINATION OF LISINIPRIL AND AMLODOPINE IN UNCONTROLLED HYPERTENSIVE PATIENTS

Abstract

Objective: To check the efficacy of double fixed-dose combination of Olmesartan (O) and Amlodopine (A) versus the fixed-dose combination of Lisinopril (L) and amlodipine (A) in obese patients with uncontrolled moderate-to-severe arterial hypertension (AH). Design and method: Design and method: 60 hypertensive patients with abdominal obesity. The first subgroup of patients (n = 30) received fixed-dose combination: O and A (20 mg/5 mg; 40 mg/10 mg), the second subgroup (n = 30) - L and A (10 mg/5 mg; 20 mg/5 mg; 20 mg/10 mg). The examinations were carried out at baseline and in 6 months. Results: Results: The frequencies of BP target levels after treatment were higher in the first subgroup than in the second (75% versus 53%, p < 0.05). According to 24-hour BP monitoring, the fixed - doses combination of O/A lowered such parameters as 24-hour systolic BP and diastolic BP, systolic BP (night) and diastolic BP (night) more significantly than fixed-doses combination L/A. The adherence to double fixed-dose combination O/A was also higher in comparison with fixed combination L/A (85% versus 61%, p < 0.05). It has been established that lower fixed-doses combination of O/A (20 mg / 5 mg) were more often used compared to L/A (20% versus 10%, P < 0.05) in this patients. At the same time, the maximum doses of these drugs were necessary to achieve target BP levels in a significantly lower number of patients receiving a fixed dose combination of O/A compared to patients on L/A (60% against 81%, p < 0.05). Conclusions: The study demonstrated superior efficacy of O/A in reducing office BP, as well as 24-h ambulatory BP versus L/A in obese patients with uncontrolled moderate-to-severe AH. Achievement of target BP levels in patients with AH and abdominal obesity was possible at lower fixed-dose combination of O/A than L/A.